Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 502 Results

Page 20 of 51« First «...10...18 192021 22...30 40 50...»Last »

August 4, 2020

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

July 31, 2020

DBV Technologies Reports First Half 2020 Financial Results

July 20, 2020

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

July 10, 2020

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

June 26, 2020

DBV Technologies Provides Operational and Business Update

June 4, 2020

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

June 2, 2020

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

April 30, 2020

DBV Technologies Reports March 31, 2020 Cash Position

April 20, 2020

DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting

April 15, 2020

Ordinary and Extraordinary General Meeting of April 20, 2020

Page 20 of 51« First «...10...18 192021 22...30 40 50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top